# Immunotherapy Rechallenge in Patients with Solid Tumors in Clinical Trials

> **NCT06612632** · PHASE1,PHASE2 · RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 100 (estimated)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** research drug in combination with Toripalimab
- **DRUG:** Toripalimab

## Key facts

- **NCT ID:** NCT06612632
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-24
- **Primary completion:** 2026-06
- **Final completion:** 2028-06
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06612632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06612632, "Immunotherapy Rechallenge in Patients with Solid Tumors in Clinical Trials". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06612632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*